Shares of the Massachusetts-based company jumped 5.5% to $2.71 in Monday morning trading.
READ: Arix Biosciences forges partnership with Fred Hutch and Evotech to invest and create new drug companies focused on oncology
The biopharma’s study was evaluating the effects of its drug Xerava on patients with complicated intra-abdominal infections.
The company released its results at the Infectious Disease Society of America’s Infectious Disease Week in San Francisco.
“These data confirm the efficacy of XERAVA in a subgroup of cIAI patients who may be at higher risk for poor outcomes, and this new analysis comes at an exciting time as we make final preparations for the commercial launch of XERAVA in the coming weeks,” said CEO Guy Macdonald in the company’s press release.
Tetraphase also reported positive safety data from its multiple-ascending dose Phase 1 study of its intravenous drug TP-6076, an antibiotic developed for the treatment of serious and life-threatening bacterial infections.
The biopharmaceutical company develops novel antibiotics for bacterial infections, including those resistant to multiple drugs and viewed as public health threats by the World Health Organization and the Centers for Disease Control and Prevention.